Back to top
more

Dynavax Technologies (DVAX)

(Real Time Quote from BATS)

$10.95 USD

10.95
195,789

-0.24 (-2.15%)

Updated Sep 11, 2024 10:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up

by Zacks Equity Research

Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.

Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up

by Zacks Equity Research

Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.

Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.

Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat

by Zacks Equity Research

Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

by Zacks Equity Research

United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates

by Zacks Equity Research

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.

Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.

Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow

by Zacks Equity Research

Bristol-Myers' (BMY) third-quarter 2023 earnings and sales beat estimates as Opdivo and new products offset losses due to oncology drug Revlimid's generic erosion.

Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat

by Zacks Equity Research

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. Shares fall.

Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View

by Zacks Equity Research

Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.

Dynavax (DVAX) to Report Q3 Earnings: Will It Beat Estimates?

by Zacks Equity Research

On Dynavax's (DVAX) third-quarter earnings call, investors' focus is likely to be on the sales performance of the company's hepatitis B vaccine, HEPLISAV-B.

Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale

by Zacks Equity Research

Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.

Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia

by Zacks Equity Research

Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The stock of the company climbs 13%.

Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.

Is it a Good Idea to Invest in Dynavax (DVAX) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Dynavax Technologies (DVAX) stock now may turn out to be a prudent move.

Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug

by Zacks Equity Research

Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.

Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up

by Zacks Equity Research

Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.

Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B

by Zacks Equity Research

Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.

Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study

by Zacks Equity Research

Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.

Wall Street Analysts See an 80.27% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 80.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain

by Zacks Equity Research

Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.

Here's Why Momentum in Dynavax Technologies (DVAX) Should Keep going

by Zacks Equity Research

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.